
    
      The regimen being tested in this study is the combination of ixazomib, daratumumab, and
      dexamethasone. This study will look at the efficacy and safety of IDd in people who have
      RRMM.

      The study will enroll approximately 60 Participants. Participants will be assigned to the
      treatment group:

      â€¢ Ixazomib 4.0 mg + Daratumumab 16.0 mg/kg + Dexamethasone 20 mg

      All participants will be asked to take Ixazomib on Days 1, 8 and 15 of each 28-day cycle plus
      Daratumumab on Days 1, 8, 15 and 22 of each 28-day cycle for Cycles 1 and 2, on Days 1 and 15
      of each 28-day cycle for Cycles 3 through 6 and on Day 1 of each 28-day cycle for Cycle 7 and
      beyond plus Dexamethasone orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle.

      This multi-center trial will be conducted in the United States, Czech Republic, France,
      Poland, Greece and the Netherlands. The overall time to participate in this study is 5 years.
      Participants will make multiple visits to the clinic, and every 12 weeks after PD until death
      or termination of the study by the sponsor.
    
  